BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36899861)

  • 1. Clinical Spectrum of
    Fernandez-Pombo A; Diaz-Lopez EJ; Castro AI; Sanchez-Iglesias S; Cobelo-Gomez S; Prado-Moraña T; Araujo-Vilar D
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput Second-generation Sequencing Technology Assisted Diagnosis of Familial Partial Lipodystrophy (Type 2 Kobberling-Dunnigan Syndrome): A Case Report.
    Deng M; Chen W; Qi Y
    Comb Chem High Throughput Screen; 2024; 27(2):346-351. PubMed ID: 37231758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
    Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.
    Vasandani C; Li X; Sekizkardes H; Adams-Huet B; Brown RJ; Garg A
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2132-41. PubMed ID: 32193531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies.
    Treiber G; Flaus Furmaniuk A; Guilleux A; Medjane S; Bonfanti O; Schneebeli S; Bernard C; Le-Moullec N; Bakiri F; Pholsena M; Rollot O; Vatier C; Jarlet E; Jéru I; Lascols O; Darcel F; Domun B; Venault A; Venault S; Jacquemont ML; Doray B; Maiza JC; Cogne M; Vigouroux C; Nobécourt E
    Eur J Endocrinol; 2021 Aug; 185(4):453-462. PubMed ID: 34292171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial partial lipodystrophy presenting as metabolic syndrome.
    Chan D; McIntyre AD; Hegele RA; Don-Wauchope AC
    J Clin Lipidol; 2016; 10(6):1488-1491. PubMed ID: 27919367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial partial lipodystrophy associated with the heterozygous LMNA mutation 1445G>A (Arg482Gln) in a Polish family.
    Drac H; Madej-Pilarczyk A; Gospodarczyk-Szot K; Gaweł M; Kwieciński H; Hausmanowa-Petrusewicz I
    Neurol Neurochir Pol; 2010; 44(3):291-6. PubMed ID: 20625965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).
    Mosbah H; Donadille B; Vatier C; Janmaat S; Atlan M; Badens C; Barat P; Béliard S; Beltrand J; Ben Yaou R; Bismuth E; Boccara F; Cariou B; Chaouat M; Charriot G; Christin-Maitre S; De Kerdanet M; Delemer B; Disse E; Dubois N; Eymard B; Fève B; Lascols O; Mathurin P; Nobécourt E; Poujol-Robert A; Prevost G; Richard P; Sellam J; Tauveron I; Treboz D; Vergès B; Vermot-Desroches V; Wahbi K; Jéru I; Vantyghem MC; Vigouroux C
    Orphanet J Rare Dis; 2022 Apr; 17(Suppl 1):170. PubMed ID: 35440056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl.
    Krawiec P; Mełges B; Pac-Kożuchowska E; Mroczkowska-Juchkiewicz A; Czerska K
    BMC Pediatr; 2016 Mar; 16():38. PubMed ID: 26976018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
    Gambineri A; Zanotti L
    Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irisin levels in LMNA-associated partial lipodystrophies.
    Bensmaïne F; Benomar K; Espiard S; Vahe C; Le Mapihan K; Lion G; Lemdani M; Chazard E; Ernst O; Vigouroux C; Pigny P; Vantyghem MC
    Diabetes Metab; 2019 Jan; 45(1):67-75. PubMed ID: 30165155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
    Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
    Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Mechanobiological Pathways Related to the Physiopathology of FPLD2.
    Varlet AA; Helfer E; Badens C
    Cells; 2020 Aug; 9(9):. PubMed ID: 32842478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene - case study of three women from one family.
    Nabrdalik K; Strózik A; Minkina-Pędras M; Jarosz-Chobot P; Młynarski W; Grzeszczak W; Gumprecht J
    Endokrynol Pol; 2013; 64(4):306-11. PubMed ID: 24002959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.